With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research ... Aranesp and Neulasta. Meanwhile, the acquisition ...

We recently compiled a list of the 11 Best Undervalued Stocks ... It is well-known for its treatments like EPOGEN, Aranesp, Neulasta, and Repatha, among others. On March 4, David Amsellem, analyst ...

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research ... Aranesp and Neulasta. Meanwhile, the acquisition of Immunex ...

Using the screener we aggregated a list of stocks trading below the forward ... It is well-known for its treatments like EPOGEN, Aranesp, Neulasta, and Repatha, among others.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

The company plans to list its key Biosimilar business by March ... novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, ...

Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion ...

Pegfilgrastim biosimilars, including Neulasta, are instrumental in preventing chemotherapy-induced neutropenia by stimulating white blood cell production and reducing infection risks. The Neulasta ...

"The addition of the Pegfilgrastim Injection to our BIOJAMP ® portfolio reinforces our commitment to providing Canadian patients with access to high-quality, cost-effective biosimilar medications," ...